Home | Contact | Employees | Incident Reporting | Sitemap | Santen Worldwide

Text Size

A
A
A

What's New

News Release

Jul 7, 2020 Announcement of New Vision Aiming to Resolve Social Issues Related to the Eye Health of People around the World
Jul 7, 2020 Santen Introduces its New Corporate Brand Name Notation and Corporate Slogan Aiming to Grow on a Globally, Going beyond the Pharmaceutical Industry
Jul 7, 2020 Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review
Jun 30, 2020 Santen and Singapore's Health-tech Start-up, Plano Form a Strategic Alliance to Tackle the Global Burden of Myopia
Jun 24, 2020 Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Jun 23, 2020 Santen's Proposed New Working Styles under the New Normal
Jun 18, 2020 Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals through Telemedicine Platform
Jun 17, 2020 Announcement of New Long-Term Vision
Jun 12, 2020 Providing Eye Care Information to Resolve Problems Caused by Excessive Screen Time
Jun 5, 2020 Bayer Yakuhin and Santen launch 'EYLEA Intravitreal Injection KIT 40mg/mL', pre-filled syringe of intravitreal VEGF Inhibitor EYLEA
May 19, 2020 Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 3)
May 12, 2020 Notice of Board of Director and Corporate Auditor Nominations
May 8, 2020 Santen Reports Fiscal 2019 Consolidated Performance
May 8, 2020 Santen and jCyte Conclude an Exclusive Licensing Contract in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa
Apr 28, 2020 Santen, Together with Nonprofit Organization, Japan Blind Football Association, to Support People with Visual Impairments Facing the COVID-19 Pandemic
Apr 27, 2020 Santen Introduces Eco-Friendly Biomass Plastic Eyedrop Bottles
Apr 1, 2020 Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)
Mar 25, 2020 Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication
Mar 24, 2020 Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 2)
Mar 13, 2020 Notice of Corporate Officer Appointments
Mar 10, 2020 Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
Mar 5, 2020 Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)
Feb 28, 2020 Santen's Measures to Combat Novel Coronavirus Infections (COVID-19) (No. 1)
Feb 27, 2020 Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd.
Feb 18, 2020 Notice of personnel change
Feb 4, 2020 Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices
Feb 4, 2020 Santen Reports the 3rd Quarter Fiscal 2019 Consolidated Performance
Jan 23, 2020 Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020!
Jan 10, 2020 Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology
Jan 6, 2020 Santen Announces the Construction of China Second Plant

Working at Advanced Vision Science

Working at Advanced Vision Science